人参皂苷Rg3联合XELOX方案对晚期胃癌患者生存期的影响

Effects of ginsenoside Rg3 combined with XELOXregimen on survival of patients with advanced gastric cancer

目的探讨人参皂苷Rg3联合卡培他滨+奥沙利铂(XELOX)方案对晚期胃癌患者生存期的影响。方法104例晚期胃癌患者随机分为对照组和观察组各52例,对照组给予XELOX方案治疗,观察组给予人参皂苷Rg3联合XELOX方案治疗,连续治疗3个月。对比2组患者治疗效果,观察患者治疗前后的CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)和肿瘤坏死因子-α(TNF-α)、癌胚抗原(CEA)水平及血清肝肾功能指标变化,记录治疗期间患者的不良反应,采用生存分析比较2组患者的中位生存期。结果观察组治疗的总有效率(42.31%)高于对照组(23.08%),差异有统计学意义(χ^(2)=4.372,P=0.037)。治疗后,观察组外周血CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)、TNF-α、CEA水平低于对照组,差异有统计学意义(P<0.05);2组血清肝肾功能指标差异无统计学意义(P>0.05)。观察组患者的中位生存期为(8.31±0.98)月,对照组为(6.24±0.72)月,2组差异有统计学意义(LogRankχ^(2)=4.747,P=0.029)。结论人参皂苷Rg3联合XELOX方案治疗晚期胃癌,临床疗效优于XELOX方案,可延长患者的生存期。

Objective To explore the effects of ginsenoside Rg3 combined with xeloda oxaliplatin-the parker(XELOX)on the survival of patients with advanced gastric cancer.Methods A total of 104 patients with advanced gastric cancer were randomly divided into a control group(n=52)and an observation group(n=52).The control group was treated with XELOX,while the observation group was treated with ginsenoside Rg3 combined with XELOX for three months.The treatment efficacy of the two groups was compared.Before and after treatment,levels of CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+),TNF-α,CEA and liver and kidney function indexes were detected.The adverse reactions during treatment were recorded.The median survival time(MST)was compared between two groups by survival analysis.Results The total effective rate of treatment in the observation group was higher than that in the control group(42.31%vs 23.08%)(χ^(2)=4.372,P=0.037).After treatment,levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in peripheral blood in the observation group were higher than those in the control group,while levels of CD8^(+),TNF-αand CEA were lower than those in the control group(P<0.05).There was no significant difference in serum liver and kidney function indexes between the two groups(P>0.05).The MST in the observation group was longer than that in the control group((8.31±0.98)months vs(6.24±0.72)months)(LogRankχ^(2)=4.747,P=0.029).Conclusions Ginsenoside Rg3 combined with XELOX can improve the clinical efficacy on advanced gastric cancer,and prolong the survival of patients.